The increasing number of gastrointestinal disorders that require endoscopic procedures is expected to drive growth in the automated endoscope reprocessor market. According to 2014 data from the National Institute of Health, the United States performs approximately 20 million endoscopic gastrointestinal procedures annually. Chemicals, contamination of patient's body fluids, skeletal muscle injuries, and radiation exposure. According to the report published in the International Journal of Surgery in 2014, the infection rate for endoscopic surgery in the gastrointestinal tract is around one in 1.8 million operations. This infection rate can be underestimated due to incomplete monitoring, asymptomatic infections, insufficient reporting, and infections with a long incubation period. AERs replace some manual steps in the endoscope reprocessing. AERs have vessels that allow the endoscopes to be immersed in a highly effective disinfecting solution (HLD). After the HLD cycle, the AERs automatically clean the processed endoscope with water to remove toxic residue from the DAN solution, followed by compressed air to dry the endoscope channels and prevent waterborne pathogens from growing during storage.
The increasing acceptance of endoscope reprocessors in hospitals for infection prevention and control should increase the global market for automated endoscope reprocessors AERs can improve reliability and improve endoscope reprocessing consistency by standardizing several important reprocessing steps, reducing the possibility of human error. The use of AERs reduces personnel exposure to harmful chemical germicides, thus minimizing the health problems associated with endoscope reprocessing.
In addition, growing government concerns about patient safety and the growth of healthcare infrastructure are contributing to the growing size of the global automated endoscopy reprocessor market. Advisory Committee (HICPAC) to issue guidelines to improve facility-level training to ensure endoscope reprocessing device qualification.